Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||eFT226 + Sotorasib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Sotorasib||Lumakras||AMG 510|AMG510|AMG-510||KRAS G12C inhibitor 23||Lumakras (sotorasib) is small molecule inhibitor that selectively targets KRAS G12C and inhibits downstream signaling, which may lead to growth inhibition of tumors harboring KRAS G12C (PMID: 31666701). Lumakras (sotorasib) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C who have received one or more prior therapy (FDA.gov).|
|eFT226||Zotatifin|eFT-226|eFT 226||Zotatifin (eFT226) is an eukaryotic initiation factor 4A1 (eIF4A1) inhibitor that promotes binding of eIF4A1 to the 5'-UTR in a sequence selective manner, which leads to repression of mRNA translation, including translation of the receptor tyrosine kinases FGFR1/2 and ERBB2 (HER2), and potentially results in induction of apoptosis and inhibition of tumor growth (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B133, PMID: 32470302).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04092673||Phase Ib/II||eFT226 + Fulvestrant eFT226 eFT226 + Sotorasib Abemaciclib + eFT226 + Fulvestrant eFT226 + Trastuzumab||Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (Zotatifin)||Recruiting||USA||0|